JP2016511257A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016511257A5 JP2016511257A5 JP2015560312A JP2015560312A JP2016511257A5 JP 2016511257 A5 JP2016511257 A5 JP 2016511257A5 JP 2015560312 A JP2015560312 A JP 2015560312A JP 2015560312 A JP2015560312 A JP 2015560312A JP 2016511257 A5 JP2016511257 A5 JP 2016511257A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- item
- composition
- dna damaging
- damaging agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361770802P | 2013-02-28 | 2013-02-28 | |
| US61/770,802 | 2013-02-28 | ||
| US201361892854P | 2013-10-18 | 2013-10-18 | |
| US61/892,854 | 2013-10-18 | ||
| PCT/US2014/019034 WO2014134311A1 (en) | 2013-02-28 | 2014-02-27 | Administration of an anti-gcc antibody-drug conjugate and a dna damaging agent in the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016511257A JP2016511257A (ja) | 2016-04-14 |
| JP2016511257A5 true JP2016511257A5 (enExample) | 2017-06-15 |
Family
ID=51428806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015560312A Pending JP2016511257A (ja) | 2013-02-28 | 2014-02-27 | 癌の治療における抗ｇｃｃ抗体−薬物複合体及びｄｎａ損傷剤の投与 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20140356383A1 (enExample) |
| EP (1) | EP2961424A4 (enExample) |
| JP (1) | JP2016511257A (enExample) |
| KR (1) | KR20150122730A (enExample) |
| CN (1) | CN105142664A (enExample) |
| CA (1) | CA2902757A1 (enExample) |
| TW (1) | TW201444577A (enExample) |
| WO (1) | WO2014134311A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX366890B (es) | 2009-10-23 | 2019-07-30 | Millennium Pharm Inc | Moléculas de anticuerpo anti - gcc y composiciones y métodos relacionados. |
| CA2871614C (en) * | 2012-04-27 | 2021-08-31 | Millennium Pharmaceuticals, Inc. | Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy |
| WO2021205325A1 (en) * | 2020-04-08 | 2021-10-14 | Pfizer Inc. | Anti-gucy2c antibodies and uses thereof |
| CN119546645A (zh) | 2022-08-05 | 2025-02-28 | 江苏恒瑞医药股份有限公司 | 特异性结合gucy2c和cd3的抗原结合分子及其医药用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010039016A1 (en) * | 2000-03-27 | 2001-11-08 | Waldman Scott A. | Use of expression profiling for identifying molecular markers useful for diagnosis of metastatic cancer |
| WO2010065293A1 (en) * | 2008-12-03 | 2010-06-10 | Boehringer Ingelheim Pharmaceuticals Inc. | Antibodies for guanylyl cyclase receptors |
| MX366890B (es) * | 2009-10-23 | 2019-07-30 | Millennium Pharm Inc | Moléculas de anticuerpo anti - gcc y composiciones y métodos relacionados. |
-
2014
- 2014-02-27 EP EP14756404.1A patent/EP2961424A4/en not_active Withdrawn
- 2014-02-27 WO PCT/US2014/019034 patent/WO2014134311A1/en not_active Ceased
- 2014-02-27 CN CN201480023899.7A patent/CN105142664A/zh active Pending
- 2014-02-27 JP JP2015560312A patent/JP2016511257A/ja active Pending
- 2014-02-27 KR KR1020157026431A patent/KR20150122730A/ko not_active Withdrawn
- 2014-02-27 CA CA2902757A patent/CA2902757A1/en not_active Abandoned
- 2014-02-27 US US14/192,632 patent/US20140356383A1/en not_active Abandoned
- 2014-02-27 TW TW103106933A patent/TW201444577A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018518454A5 (enExample) | ||
| ES2749098T3 (es) | Anticuerpos ANTI-B7-H1 y ANTI-CTLA-4 para tratar el cáncer de pulmón no microcítico | |
| JP2015532292A5 (enExample) | ||
| US20220144943A1 (en) | Anti-cd47 antibodies and uses thereof | |
| JP2019519499A5 (enExample) | ||
| JP2020502271A5 (enExample) | ||
| HRP20220399T1 (hr) | Režim doziranja imunokonjugata protutijela i sn-38 za poboljšanu učinkovitost i smanjenu toksičnost | |
| JP2018508512A5 (enExample) | ||
| JP2021513540A5 (enExample) | ||
| JP2016536361A5 (enExample) | ||
| FI3791896T3 (fi) | Claudin-18.2:n vasta-aineita sisältävä yhdistelmähoito syövän hoitoon | |
| JP2018516911A5 (enExample) | ||
| JP2019508013A5 (enExample) | ||
| JP2020527332A5 (enExample) | ||
| HRP20230517T1 (hr) | Kombinacija anti-pd-1 antitijela i radijacijske terapije za liječenje raka | |
| HRP20240338T1 (hr) | Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38 | |
| JP2018501218A5 (enExample) | ||
| HRP20201656T1 (hr) | Neutralizacija inhibitornih putova u limfocitima | |
| JP2020508317A5 (enExample) | ||
| HRP20160045T1 (hr) | Metoda lijeäśenja raka pomoä†u antagonista dll4 i kemoterapijskog sredstva | |
| JP2013507968A5 (enExample) | ||
| JP2016094424A5 (enExample) | ||
| JP2018512402A5 (enExample) | ||
| JP2019038796A5 (enExample) | ||
| JP2021511372A5 (enExample) |